Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 2, 2003, Pages 357-362

  Wang, Kai ^a   Zhou, Xiaorong ^a   Zhou, Zhongmin ^a   Tarakji, Khaldoun ^a   Carneiro, Marcelo ^a   Penn, Marc S ^a   Murray, Daniel ^a   Klein, Allan ^a   Humphries, Robert G ^b   Turner, Jonathan ^b   Thomas, James D ^a   Topol, Eric J ^a   Michael Lincoff, A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Myocardial contrast echocardiography; Myocardial tissue perfusion; P2Y12 receptor; Thrombosis

Indexed keywords

6 N (2 METHYLTHIOETHYL) 2 (3,3,3 TRIFLUOROPROPYLTHIO)ADENOSINE PHOSPHATE; ACETYLSALICYLIC ACID; HEPARIN; PURINE P2Y RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; CANGRELOR; DRUG DERIVATIVE; MEMBRANE PROTEIN; PURINE P2 RECEPTOR; PURINE P2Y12 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD VESSEL INJURY; BOLUS INJECTION; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DOG; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; THROMBOCYTE AGGREGATION; THROMBOSIS; ANIMAL; BLEEDING TIME; BLOOD CLOTTING; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; DISEASE MODEL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART INFARCTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; NON-PROGRAMMATIC; PATHOLOGY; PHYSIOLOGY; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

NON-PROGRAMMATIC;

ADENOSINE MONOPHOSPHATE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; BLEEDING TIME; BLOOD COAGULATION; CORONARY CIRCULATION; CORONARY RESTENOSIS; CORONARY STENOSIS; DISEASE MODELS, ANIMAL; DOGS; DRUG COMBINATIONS; ECHOCARDIOGRAPHY; FEMALE; HEPARIN; INFUSIONS, INTRAVENOUS; MALE; MEMBRANE PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037289827     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000052669.50791.0B     Document Type: Article

References (28)

1. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, Masuyama T, Kitabatake A, Minamino T. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992;85:1699-1705.
2. Macfarlane DE, Mills DCB. The effect of ATP on platelets: evidence against the central role of released ADP in primary aggregation. Blood. 1975;46:309-320.
3. 2T purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. Br J Pharmacol. 1995;115:1110-1116.
4. 2T purinoceptors. Br J Pharmacol. 1994;113:1057-1063.
5. Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J. 1986;233:309-319.
6. Hollopeter G, Jantzen H-M, Vincent D, Li G, England L, Ramakrishnan V, Yang R-B, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207.
7. Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Manucci PM. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost. 1991;66:694-699.
8. Savi P, Nurden P, Nurden A, Levy-Toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets. 1998;9:251-255.
9. Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1993;4:252-261.
10. Boneu B, Destelle G, on behalf of the CAPRIE Study Group. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost. 1996;76:939-943.
11. Humphries RG, Robertson MJ, Leff P. A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci. 1995;16:179-181.
12. 2T-receptor: a novel approach to antithrombotic therapy. J Med Chem. 1999;42:213-220.
13. 2T receptor antagonist AR-C69931MX in a canine model. JPET. 2000;295:492-499.
14. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine, a model for in vivo evaluation of antithrombotic agents. Thromb Res. 1980;17:841-853.
15. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation. 1994;89: 1802-1809.
16. Austin GE, Tuvlin MB, Martino-Salzman D, Hunter RL, Justicz AG, Thompson NK, Brooks AC. Determination of regional myocardial blood flow using fluorescent microspheres. Am J Cardiovasc Pathol. 1993;4: 352-357.
17. Tiemann K, Lohmeier S, Kuntz S, Koster J, Pohl C, Bums P, Nanda NC, Luderitz B, Becher H. Real-time contrast echo assessment of myocardial perfusion at low emission power: first experimental and clinical results using power pulse inversion imaging. Echocardiography. 1999;16: 799-809.
18. Masugata H, Peters B, Lafitte S, Strachan GM, Ohmori K, Demaria AN. Quantitative assessment of myocardial perfusion during graded coronary stenosis by real-time myocardial contrast echo refilling curves. J Am Coll Cardiol. 2001;37:262-269.
19. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation, I: evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273: 2024-2029.
20. 2T-receptors. Br J Pharmacol. 2000;129:275-282.
21. 2T-receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925-934.
22. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
23. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
24. Savi P, Combalbert J, Gaich C, Rouchon M-C, Maffrand J-P, Berger Y, Herbert J-M. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72:313-317.
25. Humbert M, Nurden P, Bihour C, Pasquet JM, Winckler J, Heilmann E, Savi P, Herbert JM, Kunicki TJ, Nurden AT. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol. 1996;16:1532-1543.
26. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden AT. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest. 1995;95: 1612-1622.
27. 12 in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol. 2002;22:686-691.
28. 2T-receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001;85:401-407.